Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention
作者： Martin Braddock , Anthony Quinn
DOI: 10.1038/NRD1342
关键词:
摘要: The cytokine interleukin-1 (IL-1) is important in many human diseases, and drives a wide range of inflammatory responses number cell types. Biological agents that target IL-1 neutralization have shown efficacy patients with rheumatoid arthritis. Recently, new classes compounds production or processing, regulatory steps on the pathway, are being investigated as drugs for management disease. Such will utility numerous conditions.
nature.com
sci-hub.se 参考文章(96)
Roy M. Fleischmann, Joy Schechtman, Ralph Bennett, Malcolm L. Handel, Gerd-Rudiger Burmester, John Tesser, Dennis Modafferi, Jennifer Poulakos, Gordon Sun, Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis & Rheumatism. ,vol. 48, pp. 927- 934 ,(2003) , 10.1002/ART.10870
Barry Bresnihan, Jos� Maria Alvaro-Gracia, Mark Cobby, Michael Doherty, Zlatko Domljan, Paul Emery, George Nuki, Karel Pavelka, Rolf Rau, Blaz Rozman, Iain Watt, Bryan Williams, Roger Aitchison, Dorothy McCabe, Predrag Musikic, Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist Arthritis & Rheumatism. ,vol. 41, pp. 2196- 2204 ,(1998) , 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2
Brian Henderson, Robert C. Thompson, Tim Hardingham, Joanne Lewthwaite, Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist Cytokine. ,vol. 3, pp. 246- 249 ,(1991) , 10.1016/1043-4666(91)90023-7
D. Cerretti, C. Kozlosky, B Mosley, N Nelson, K Van Ness, T. Greenstreet, C. March, Kronheim, T Druck, L. Cannizzaro, al. et, Molecular cloning of the interleukin-1 beta converting enzyme Science. ,vol. 256, pp. 97- 100 ,(1992) , 10.1126/SCIENCE.1373520
Aris N. Economides, Laura Rocco Carpenter, John S. Rudge, Vivien Wong, Ellen M. Koehler-Stec, Christopher Hartnett, Erica A. Pyles, Xiaobing Xu, Thomas J. Daly, Michael R. Young, James P. Fandl, Frank Lee, Scott Carver, Jennifer McNay, Kevin Bailey, Swayampakula Ramakanth, Renta Hutabarat, Tammy T. Huang, Czeslaw Radziejewski, George D. Yancopoulos, Neil Stahl, Cytokine traps: multi-component, high-affinity blockers of cytokine action Nature Medicine. ,vol. 9, pp. 47- 52 ,(2003) , 10.1038/NM811
Stéphane Liège, Sophie Layé, Kang-Sheng Li, Elisabeth Moze, Pierre J Neveu, Interleukin 1 receptor accessory protein (IL-1RAcP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1β Journal of Neuroimmunology. ,vol. 110, pp. 134- 139 ,(2000) , 10.1016/S0165-5728(00)00331-3
G. V. Campion, M. E. Lebsack, J. Lookabaugh, G. Gordon, , Dose‐range and dose‐frequency study of recombinant human interleukin‐1 receptor antagonist in patients with rheumatoid arthritis Arthritis & Rheumatism. ,vol. 39, pp. 1092- 1101 ,(1996) , 10.1002/ART.1780390704
Kimberly Burns, Fabio Martinon, Christoph Esslinger, Heike Pahl, Pascal Schneider, Jean-Luc Bodmer, Francesco Di Marco, Lars French, Jürg Tschopp, MyD88, an adapter protein involved in interleukin-1 signaling. Journal of Biological Chemistry. ,vol. 273, pp. 12203- 12209 ,(1998) , 10.1074/JBC.273.20.12203
S. Spence McCachren, Paula K. Greer, James E. Niedel, Regulation of human synovial fibroblast collagenase messenger RNA by interleukin-1. Arthritis & Rheumatism. ,vol. 32, pp. 1539- 1545 ,(1989) , 10.1002/ANR.1780321207
Yebin Jiang, Harry K. Genant, Iain Watt, Mark Cobby, Barry Bresnihan, Roger Aitchison, Dorothy McCabe, A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of genant and larsen scores Arthritis & Rheumatism. ,vol. 43, pp. 1001- 1009 ,(2000) , 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P